Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer
- PMID: 38775501
- PMCID: PMC11110966
- DOI: 10.1590/1806-9282.20231115
Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer
Abstract
Objective: Endometrial cancer is the most common gynecological cancer in developed countries, with a majority of cases being low-grade endometrioid endometrial cancer. Identifying risk factors for disease recurrence and poor prognosis is critical. This study aimed to assess the correlation between preoperative cancer antigen-125 levels and disease recurrence in early-stage endometrioid endometrial cancer patients.
Methods: The study was a retrospective analysis of 217 patients diagnosed with endometrioid endometrial cancer who underwent surgical treatment at a university-affiliated tertiary hospital between 2016 and 2022. Patients were divided into two groups based on their preoperative cancer antigen-125 levels and compared with clinicopathological findings and disease recurrence. Disease-free survival rates were calculated, and logistic regression analysis was performed to determine independent factors affecting disease-free survival.
Results: The mean age of patients was 61.59±0.75 years, and the mean follow-up time was 36.95±1.18 months. The mean cancer antigen-125 level was 27.80±37.81 IU/mL. The recurrence rate was significantly higher in the group with elevated cancer antigen-125 levels (p=0.025). Disease-free survival was lower in patients with elevated cancer antigen-125 compared with those with normal levels (p=0.005). Logistic regression analysis revealed that elevated cancer antigen-125 levels were associated with disease recurrence (OR: 3.43, 95%CI 1.13-10.37, p=0.029).
Conclusion: The findings of this study suggest that preoperative cancer antigen-125 levels can be used as a predictor of disease recurrence in early-stage endometrioid endometrial cancer patients. cancer antigen-125 levels may be a useful tool for risk stratification and patient management in endometrial cancer.
Conflict of interest statement
Conflicts of interest: the authors declare there is no conflicts of interest.
Figures
Similar articles
-
The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.Asian Pac J Cancer Prev. 2016;17(2):497-501. doi: 10.7314/apjcp.2016.17.2.497. Asian Pac J Cancer Prev. 2016. PMID: 26925634
-
What is the predictive value of preoperative CA 125 level on the survival rate of type 1 endometrial cancer?Turk J Med Sci. 2021 Feb 26;51(1):335-341. doi: 10.3906/sag-2005-331. Turk J Med Sci. 2021. PMID: 32979897 Free PMC article.
-
Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.J BUON. 2016 Nov-Dec;21(6):1491-1495. J BUON. 2016. PMID: 28039713
-
Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer.J Obstet Gynaecol Can. 2011 Aug;33(8):844-850. doi: 10.1016/S1701-2163(16)34988-X. J Obstet Gynaecol Can. 2011. PMID: 21846440
-
[Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2018 Dec 25;53(12):816-822. doi: 10.3760/cma.j.issn.0529-567x.2018.12.004. Zhonghua Fu Chan Ke Za Zhi. 2018. PMID: 30585019 Chinese.
Cited by
-
Clinicopathological Significance of Claudin-6 Immunoreactivity in Low-grade, Early-stage Endometrioid Endometrial Carcinoma.In Vivo. 2025 Jan-Feb;39(1):367-374. doi: 10.21873/invivo.13837. In Vivo. 2025. PMID: 39740870 Free PMC article.
-
Factors influencing disease-free survival after radical endometrial cancer surgery: an analysis of the competitive risk prediction mode.Am J Transl Res. 2025 Feb 15;17(2):1265-1276. doi: 10.62347/BRVI1759. eCollection 2025. Am J Transl Res. 2025. PMID: 40092113 Free PMC article.
References
-
- Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742–1750. doi: 10.1016/j.ejca.2015.05.015. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources